Qiagen (NYSE:QGEN), a German provider of sample and assay technologies, has received emergency use authorisation for a new COVID-19 test from the US drugs regulator FDA, Reuters news agency reported on Monday.
The company was quoted as stating: "This polymerase chain reaction (PCR) multiplex test will be an important tool now and in upcoming winter seasons for simultaneous qualitative detection and differentiation of influenzas A and B, respiratory syncytial virus (RSV) and SARS-CoV-2 infections within 80 minute."
Century Health partnerss with Tessel Biosciences to advance early drug development in COPD
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema
PureTech clears key FDA milestone for Phase 3 development of deupirfenidone
Orano Med and Roche advance pretargeted radioimmunotherapy into clinical phase
bioMérieux launches equine endocrinology tests to expand point-of-care diagnostics
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Neola Medical secures US patent for disposable lung monitoring probes
Spinogenix reports approval of 'tazbentetol' as non-proprietary name for SPG302